Porton Pharma Solutions Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Nianfeng Ju

Chief Executive Officer (CEO)

CN¥1.9m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	10.8%
Permanencia media de la dirección	2.6yrs
Promedio de permanencia en la Junta Directiva	2.6yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Nianfeng Ju (52 yo)

no data

Permanencia

CN¥1,931,300

Compensación

Mr. Nianfeng Ju serves as General Manager of Porton Imp & Exp Ltd. Nianfeng Ju served as the General Manager of Porton Co., Ltd. He serves as a General Manager of Porton Pharma Solutions Ltd.Mr. Ju serves...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Nianfeng Ju	Chairman & GM	no data	CN¥1.93m	10.8% CN¥ 1.0b
Hui Chen	Deputy GM & CFO	2.6yrs	CN¥1.59m	sin datos
Yinchun Bai	Senior Deputy GM & COO	2.6yrs	CN¥1.65m	0.029% CN¥ 2.7m
Pi Wei	Deputy General Manager & Secretary	2.6yrs	CN¥714.90k	0.0083% CN¥ 773.6k
Zhongneng Wang	Deputy General Manager	2.6yrs	CN¥1.39m	0.026% CN¥ 2.4m
Fengping Wang	Deputy General Manager	2.6yrs	CN¥2.09m	0.020% CN¥ 1.9m
Qi Chen	Deputy General Manager	1.3yrs	sin datos	sin datos
Xiongbin Ma	Deputy General Manager	1.3yrs	sin datos	sin datos
Yuanming Huang	Deputy General Manager	1.3yrs	sin datos	sin datos

2.6yrs

Permanencia media

47yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 300363 se considera experimentado (2.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Nianfeng Ju	Chairman & GM	no data	CN¥1.93m	10.8% CN¥ 1.0b
Weiqiang Yang	Non Independent Director	3.3yrs	CN¥180.00k	sin datos
Guohua Cao	Independent Director	4.2yrs	CN¥180.00k	sin datos
Hui Zeng	Employee Representative Supervisor	no data	CN¥212.80k	sin datos
Lin Yuan	Independent Director	2.6yrs	CN¥180.00k	sin datos
Jinwei Pang	Independent Director	2.6yrs	CN¥180.00k	sin datos
Yongqing Tan	Non-Employee Supervisory Board Chairman	no data	sin datos	sin datos
Ying Xue	Non-Independent Director	4.2yrs	CN¥180.00k	0.0027% CN¥ 252.2k
Jun Zhu	Director	1.8yrs	sin datos	sin datos
Lina Hu	Non-Independent Director	2.6yrs	CN¥180.00k	sin datos
Guojun Cao	Non-Independent Director	2.6yrs	CN¥180.00k	sin datos
Yuchen Wu	Non-Employee Supervisor	2.6yrs	sin datos	sin datos

2.6yrs

Permanencia media

56.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 300363 no se considera experimentada (2.6 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Porton Pharma Solutions Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

High number of new directors

High number of new directors

High number of new and inexperienced directors

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Recent updates

Third quarter 2024 earnings released: CN¥0.068 loss per share (vs CN¥0.075 profit in 3Q 2023)

New minor risk - Share price stability

Porton Pharma Solutions Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: CN¥0.14 loss per share (vs CN¥0.20 profit in 2Q 2023)

New major risk - Revenue and earnings growth

Porton Pharma Solutions Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Porton Pharma Solutions Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: CN¥0.17 loss per share (vs CN¥0.56 profit in 1Q 2023)

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment deteriorates as stock falls 16%

Porton Pharma Solutions Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

New major risk - Revenue and earnings growth

New major risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.075 (vs CN¥0.67 in 3Q 2022)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥1.53 in 2Q 2022)

Porton Pharma Solutions Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Upcoming dividend of CN¥1.11 per share at 3.2% yield

Full year 2022 earnings released: EPS: CN¥3.70 (vs CN¥0.97 in FY 2021)

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.23 in 2Q 2021)

Porton Pharma Solutions Ltd. (SZSE:300363) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

High number of new directors

High number of new and inexperienced directors

First quarter 2022 earnings released: EPS: CN¥0.70 (vs CN¥0.16 in 1Q 2021)

Porton Pharma Solutions Ltd. Announces Final Dividend for 2021, Payable on 28 April 2022

Porton Pharma Solutions Ltd. Approves Cash Dividend for 2021

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.20 in 3Q 2020)

Porton Pharma Solutions Ltd. (SZSE:300363) agreed to acquire 70% stake in Hubei Yuyang Pharmaceutical Co., Ltd. from a group of shareholders for approximately CNY 170 million.

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.16 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.09 in 1Q 2020)

Porton Pharma Solutions Ltd. Announces on 15 March 2021 the Profit Distribution Proposal for 2020

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 06, 2021

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.35 in FY 2019)

Investor sentiment deteriorated over the past week

Revenue beats expectations

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.35 in FY 2019)

New 90-day high: CN¥46.67

Zhangjiagang Zhuoyuan Investment Partnership (Limited Partnership) completed the acquisition of 5.24% stake in Porton Pharma Solutions Ltd. (SZSE:300363) from Ju Nianfeng, Tao Rong, and Zhang Hebing.

Porton Pharma Solutions Ltd. to Report Fiscal Year 2020 Results on Mar 13, 2021

New 90-day high: CN¥42.13

Investor sentiment improved over the past week

New 90-day high: CN¥39.66

Third quarter earnings released

Porton Pharma Solutions Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Market bids up stock over the past week

New 90-day high: CN¥38.90

Porton Pharma Solutions Ltd. Announces Board Changes

Earnings released

Porton Pharma Solutions Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta